Monoclonal Antibodies Targeting HCMV Pentamer Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Human Cytomegalovirus (HCMV) infections lack effective neutralizing antibodies that can target the Pentamer protein complex, which is crucial for preventing viral entry into various cell types, particularly in epithelial and endothelial cells.
Innovation Solution
Development of monoclonal antibodies and their antigen binding fragments that specifically bind to the HCMV Pentamer protein complex, including humanized versions of murine antibodies (m26B6, m23C2, and m2C7) that target diverse epitopes, allowing for neutralization of the virus and potential therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for HCMV infections, then existing therapy options are limited, but effective neutralizing antibodies targeting the Pentamer protein complex are lacking
Solution Approach 1:
The patent segments the antibody development process by creating multiple monoclonal antibodies (m26B6, m23C2, m2C7) that target different epitopes on the Pentamer protein complex. This segmentation allows for diverse neutralization mechanisms and provides versatility in treating HCMV infections through multiple antibody options rather than a single treatment approach.
Solution Approach 2:
The patent achieves universality by developing monoclonal antibodies that can neutralize HCMV across multiple cell types including epithelial cells, endothelial cells, and fibroblasts. The antibodies demonstrate broad-spectrum neutralizing activity against HCMV strains, making them universally applicable treatments for different HCMV infection scenarios.
2Reliability
If monoclonal antibodies are developed to target diverse epitopes on Pentamer, then neutralizing potency increases, but development complexity increases
Solution Approach 1:
The patent applies segmentation by isolating multiple monoclonal antibodies from immunized mice, each targeting distinct epitopes on the Pentamer complex. This approach divides the complex task of creating a potent neutralizing agent into manageable segments (individual mAbs), which can then be characterized and potentially combined for enhanced efficacy.
Solution Approach 2:
The patent utilizes parameter changes by humanizing murine antibodies to improve their therapeutic applicability. The humanization process modifies the antibody sequences while preserving epitope specificity, changing physical parameters such as immunogenicity and half-life, thereby maintaining neutralizing potency while reducing development and clinical translation complexity.
3Reliability
If antibodies are designed to block viral entry in epithelial and endothelial cells, then prevention of primary infection improves, but broader cellular coverage is limited
Solution Approach 1:
The patent achieves universality by demonstrating that the developed monoclonal antibodies can neutralize HCMV in multiple cell types beyond just epithelial and endothelial cells, including fibroblasts. This multi-functional capability ensures broad cellular coverage while maintaining reliable prevention of primary infection across diverse tissue types.
Solution Approach 2:
The patent segments the viral entry process by targeting the Pentamer protein complex, which is involved in receptor binding and membrane fusion. By segmenting the neutralization mechanism to focus on this critical entry point, the antibodies effectively block viral entry across multiple cell types that express the relevant receptors, thereby expanding cellular coverage while maintaining specialized anti-entry function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies demonstrate high neutralizing potency against HCMV in epithelial cells and fibroblasts, providing a promising therapeutic approach to prevent or treat HCMV infections by blocking viral entry and replication.
Implementation Method 1
isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to HCMV Pentamer
Data Source
AI summary
Monoclonal antibodies and antigen binding fragments that specifically bind to the Human Cytomegalovirus (HCMV) pentamer protein complex (gH/gL/UL128/UL130/UL131A) or other gH-containing complexes, and uses thereof.